Shaanxi Meibang Pharmaceutical Group Co., Ltd. (605033.SS)
CNY 12.67
(-0.63%)
CNY 12.67
(-0.63%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 84.13 Million CNY | -46.28% |
| 2022 | 150.04 Million CNY | 8.49% |
| 2021 | 154.61 Million CNY | 71.13% |
| 2020 | 100.89 Million CNY | -1.99% |
| 2019 | 97.79 Million CNY | 20.52% |
| 2018 | 79.92 Million CNY | -0.92% |
| 2017 | 79.11 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.25 Million CNY | -88.87% |
| 2024 Q3 | 1.07 Million CNY | -82.47% |
| 2024 Q1 | 56.68 Million CNY | 402.48% |
| 2023 Q2 | 11.62 Million CNY | -86.52% |
| 2023 FY | - CNY | -46.28% |
| 2023 Q4 | -10.78 Million CNY | -23.8% |
| 2023 Q3 | -8.7 Million CNY | -174.89% |
| 2023 Q1 | 86.29 Million CNY | 248.55% |
| 2022 Q3 | -16.2 Million CNY | -148.72% |
| 2022 Q2 | 33.26 Million CNY | -73.92% |
| 2022 Q1 | 127.54 Million CNY | 81.73% |
| 2022 FY | - CNY | 8.49% |
| 2022 Q4 | 24.75 Million CNY | 252.79% |
| 2021 FY | - CNY | 71.13% |
| 2021 Q4 | 70.18 Million CNY | 789.65% |
| 2021 Q3 | -10.17 Million CNY | -130.43% |
| 2021 Q2 | 33.44 Million CNY | -48.99% |
| 2021 Q1 | 65.56 Million CNY | 207.24% |
| 2020 FY | - CNY | -1.99% |
| 2020 Q4 | 21.34 Million CNY | 176.79% |
| 2020 Q3 | -27.79 Million CNY | -165.01% |
| 2020 Q2 | 42.75 Million CNY | -29.54% |
| 2020 Q1 | 60.67 Million CNY | 0.0% |
| 2019 FY | - CNY | 20.52% |
| 2018 FY | - CNY | -0.92% |
| 2017 FY | - CNY | 0.0% |